GigaMune

Executive Summary

GigaMune is a San Diego-based biotechnology company pioneering in vivo cell therapy for cancer and inherited blood disorders. Founded in 2020, the company aims to overcome the limitations of traditional ex vivo cell therapy manufacturing by directly delivering gene therapy vectors to patients, thereby reducing complexity, cost, and treatment delays. Central to GigaMune's approach is its advanced computational and high-throughput screening platform, which enables the design of highly targeted viral vectors and chimeric antigen receptors (CARs) to improve specificity, efficacy, and safety. The company's vision is to make cell therapy accessible as an off-the-shelf treatment option, potentially transforming the standard of care for a wide range of hematologic malignancies and genetic diseases. While still in a preclinical stage, GigaMune has the potential to disrupt the cell therapy landscape if its platform successfully translates into clinical candidates. The company operates in a competitive field, with other players pursuing similar in vivo approaches, but GigaMune's computational differentiation could provide an edge. Near-term focus is on securing funding, advancing lead programs toward investigational new drug (IND)-enabling studies, and forging partnerships to leverage its technology. Given the early stage, the company carries typical development and financing risks, but the promise of a more scalable and cost-effective cell therapy paradigm supports a moderate conviction level.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Round70% success
• Q1 2027Preclinical Proof-of-Concept Data in Lead Indication60% success
• TBDStrategic Licensing or Collaboration Agreement40% success